Icotrokinra is a macrocyclic peptide and oral interleukin-23 receptor antagonist peptide indicated for the treatment of moderate-to-severe plaque psoriasis. It was jointly discovered and developed by Protagonist and Johnson & Johnson and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
- Mechanism
- Curator reviewed · 5 references
Icotrokinra is a first-in-class targeted oral peptide that selectively binds to the IL-23 receptor (IL-23R) with high affinity, demonstrated by a dissociation constant of 7 pM. By blocking the IL-23 receptor, the drug antagonizes the binding of IL-23, a naturally occurring cytokine involved in inflammatory and immune responses. This antagonism inhibits the IL-23/IL-23R-dependent release of proinflammatory cytokines that underpin the inflammatory response in moderate-to-severe plaque psoriasis.
- Primary indication
- Icotrokinra is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.Curator reviewed · 4 structured indications
- Formula / weight
- C90H120N20O22S2 · 1898.19 g/mol (avg)
- First approval
- United States, 2026
- Code names
- JNJ-2113 · JNJ-77242113 · PN-21235
- Brand names
Resolves to
IVFNYXYPMJQSGF-HBIKWSQCSA-NSMILESC[C@@H](O)[C@@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(C)=O)C(C)(C)SSC(C)(C)[C@H](NC(=O)[C@H](CCCCNC(C)=O)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3C)NC1=O)C(=O)N[C@@H](CC1=CC=C(OCCN)C=C1)C(=O)N[C@@H](CC1=CC2=CC=CC=C2C=C1)C(=O)NC1(CCOCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CN=C1)C(=O)N(C)CC(N)=OWhat you can answer from here — as of September 24, 2026
Which drugs share a target with Icotrokinra, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account